Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of pTVG-HP +/- pTVG-AR DNA Vaccine and Pembrolizumab in mCRPC
NCT04090528Phase 2Active, not recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Oct 2019
- Primary completion
- Nov 2024
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of pTVG-HP plasmid DNA vaccine, pTVG-AR in castration-resistant prostate cancer (CRPC), sponsored by University of Wisconsin–Madison. Started Oct 2019; status: active, not recruiting.
02
Drugs
pTVG-HP plasmid DNA vaccinepTVG-AR
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT04090528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04090528.